Drugs / IBI389
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05164458 | Mar 2022 → Apr 2024 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-06-03 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer and Gastric Cancer innoventbio.com ↗
In the presented clinical data, IBI389 has shown promising efficacy in advanced G/GEJ tumors and PDAC, including those subjects with low and moderate CLDN18.2 expression. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-06-03 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer and Gastric Cancer innoventbio.com ↗ |
| 2022-03-29 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Announces First Patient Dosing of Claudin18.2/CD3 Bispecific Antibody IBI389 in Phase 1a/1b Clinical Trial for Advanced Solid Tumor innoventbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI389 | “IBI389 is a novel anti-Claudin18.2 × CD3 bispecific antibody designed to engage T cells by binding CD3 and Claudin18.2, thereby induce immune synapse formation.” PMID 41540424 ↗ Jan 2026 |
| Route | Intravenous | “IBI 389 IV Q2\~Q3W Day 1” NCT05164458 ↗ |